logo

Gilead Sciences Inc. (GILD)



Trade GILD now with
  Date
  Headline
12/10/2018 1:01:48 AM Gilead Sciences Appoints Roche Executive Daniel O’Day As Chairman And CEO, Effective March 1, 2019
12/4/2018 8:32:38 AM Gilead Sciences: China’s NMPA Approves Harvoni For Treatment Of Chronic Hepatitis C Virus Genotype 1-6
12/3/2018 8:01:49 PM Kite Updates Data From ZUMA-3 Study Of KTE-X19 In Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
12/2/2018 5:43:23 PM Kite Announces Two-Year Data For Yescartain Patients With Refractory Large B-Cell Lymphoma
11/18/2018 10:32:56 PM China NMPA Approves Gilead’s Vemlidy For Chronic HBV Infection
11/9/2018 8:03:33 AM Gilead Reports New Data From Clinical Development Program For Advanced Fibrosis Due To Nonalcoholic Steatohepatitis
11/9/2018 8:02:09 AM Gilead Reports Positive Phase 2 Results For GS-9674 In Primary Sclerosing Cholangitis At The Liver Meeting 2018
10/31/2018 8:32:53 AM Gilead Sciences, Tango Therapeutics Announce Collaboration To Develop Next-Generation Targeted Immuno-Oncology Therapies
10/30/2018 6:39:59 AM Gilead Sciences Says Biktarvy Showed High Efficacy And High Barrier To Resistance Through 96 Weeks
10/25/2018 4:35:10 PM Gilead Sciences Inc. (GILD) Has Raised Its 2018 Revenue Estimate To $20.8 - $21.3 Bln From $20.0 - $21.0 Bln
10/25/2018 4:27:42 PM Gilead Sciences Q3 EPS $1.60 Vs. $2.06 Year Ago
10/25/2018 4:15:45 PM Gilead Sciences Declares Quarterly Dividend Of $0.57, Payable Dec. 28/ Record Dec. 14
10/25/2018 4:03:57 PM Gilead Sciences Inc. (GILD) Declares Quarterly Dividend of $ 0.57, Record Date 12/14/2018